Aktiengesellschaft Bayer - Net Worth and Insider Trading

Aktiengesellschaft Bayer Net Worth

The estimated net worth of Aktiengesellschaft Bayer is at least $732 Million dollars as of 2024-06-08. Aktiengesellschaft Bayer is the 10% Owner of IPSCO Tubulars Inc and owns about 12,675,838 shares of IPSCO Tubulars Inc (IPSC) stock worth over $391 Million. Aktiengesellschaft Bayer is the 10% Owner of Elanco Animal Health Inc and owns about 18,446,429 shares of Elanco Animal Health Inc (ELAN) stock worth over $336 Million. Aktiengesellschaft Bayer is also the 10% Owner of CRISPR Therapeutics AG and owns about 75,945 shares of CRISPR Therapeutics AG (CRSP) stock worth over $4 Million. Details can be seen in Aktiengesellschaft Bayer's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Aktiengesellschaft Bayer has not made any transactions after 2021-06-22 and currently still holds the listed stock(s).

Transaction Summary of Aktiengesellschaft Bayer

To

Aktiengesellschaft Bayer Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Aktiengesellschaft Bayer owns 6 companies in total, including Elanco Animal Health Inc (ELAN) , CRISPR Therapeutics AG (CRSP) , and Pyxis Oncology Inc (PYXS) among others .

Click here to see the complete history of Aktiengesellschaft Bayer’s form 4 insider trades.

Insider Ownership Summary of Aktiengesellschaft Bayer

Ticker Comapny Transaction Date Type of Owner
ELAN Elanco Animal Health Inc 2020-12-03 10 percent owner
CRSP CRISPR Therapeutics AG 2018-01-05 10 percent owner
PYXS Pyxis Oncology Inc 2021-10-07 10 percent owner
LIMIT LIMIT 2021-06-17 10 percent owner
LIMIT LIMIT 2022-06-08 10 percent owner
LIMIT LIMIT 2023-06-15 10 percent owner

Aktiengesellschaft Bayer Latest Holdings Summary

Aktiengesellschaft Bayer currently owns a total of 3 stocks. Among these stocks, Aktiengesellschaft Bayer owns 12,675,838 shares of IPSCO Tubulars Inc (IPSC) as of June 22, 2021, with a value of $391 Million and a weighting of 53.49%. Aktiengesellschaft Bayer owns 18,446,429 shares of Elanco Animal Health Inc (ELAN) as of December 3, 2020, with a value of $336 Million and a weighting of 45.91%. Aktiengesellschaft Bayer also owns 75,945 shares of CRISPR Therapeutics AG (CRSP) as of January 5, 2018, with a value of $4 Million and a weighting of 0.6%.

Latest Holdings of Aktiengesellschaft Bayer

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
IPSC IPSCO Tubulars Inc 2021-06-22 12,675,838 30.88 391,429,877
ELAN Elanco Animal Health Inc 2020-12-03 18,446,429 18.21 335,909,472
CRSP CRISPR Therapeutics AG 2018-01-05 75,945 57.87 4,394,937

Holding Weightings of Aktiengesellschaft Bayer


Aktiengesellschaft Bayer Form 4 Trading Tracker

According to the SEC Form 4 filings, Aktiengesellschaft Bayer has made a total of 1 transactions in IPSCO Tubulars Inc (IPSC) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in IPSCO Tubulars Inc is the acquisition of 750,000 shares on June 22, 2021, which cost Aktiengesellschaft Bayer around $15 Million.

According to the SEC Form 4 filings, Aktiengesellschaft Bayer has made a total of 1 transactions in Elanco Animal Health Inc (ELAN) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Elanco Animal Health Inc is the sale of 54,500,000 shares on December 3, 2020, which brought Aktiengesellschaft Bayer around $1.6 Billion.

According to the SEC Form 4 filings, Aktiengesellschaft Bayer has made a total of 0 transactions in CRISPR Therapeutics AG (CRSP) over the past 5 years. The most-recent trade in CRISPR Therapeutics AG is the acquisition of 527,472 shares on January 5, 2018, which cost Aktiengesellschaft Bayer around $12 Million.

Insider Trading History of Aktiengesellschaft Bayer

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Aktiengesellschaft Bayer Trading Performance

GuruFocus tracks the stock performance after each of Aktiengesellschaft Bayer's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Aktiengesellschaft Bayer is 59.16%. GuruFocus also compares Aktiengesellschaft Bayer's trading performance to market benchmark return within the same time period. The performance of stocks bought by Aktiengesellschaft Bayer within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Aktiengesellschaft Bayer's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Aktiengesellschaft Bayer

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 32.9 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 36.33 LIMIT LIMIT LIMIT LIMIT LIMIT

Aktiengesellschaft Bayer Ownership Network

Ownership Network List of Aktiengesellschaft Bayer

No Data

Ownership Network Relation of Aktiengesellschaft Bayer

Insider Network Chart

Aktiengesellschaft Bayer Owned Company Details

What does Elanco Animal Health Inc do?

Who are the key executives at Elanco Animal Health Inc?

Aktiengesellschaft Bayer is the 10 percent owner of Elanco Animal Health Inc. Other key executives at Elanco Animal Health Inc include EVP & MANUFACTURING AND QUALITY Grace Mcardle , See remarks Timothy J Bettington , and director & Pres. & Chief Executive Officer Jeffrey N Simmons .

Elanco Animal Health Inc (ELAN) Insider Trades Summary

Over the past 18 months, Aktiengesellschaft Bayer made no insider transaction in Elanco Animal Health Inc (ELAN). Other recent insider transactions involving Elanco Animal Health Inc (ELAN) include a net purchase of 40,000 shares made by R David Hoover , a net purchase of 30,000 shares made by William F Doyle , and a net purchase of 15,000 shares made by Jeffrey N Simmons .

In summary, during the past 3 months, insiders sold 0 shares of Elanco Animal Health Inc (ELAN) in total and bought 15,000 shares, with a net purchase of 15,000 shares. During the past 18 months, 0 shares of Elanco Animal Health Inc (ELAN) were sold and 88,100 shares were bought by its insiders, resulting in a net purchase of 88,100 shares.

Elanco Animal Health Inc (ELAN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Elanco Animal Health Inc Insider Transactions

No Available Data

Aktiengesellschaft Bayer Mailing Address

Above is the net worth, insider trading, and ownership report for Aktiengesellschaft Bayer. You might contact Aktiengesellschaft Bayer via mailing address: Bayerwerk, Gebaeude W11, Kaiser-wilhelm-allee, Leverkusen 2m D-51368.

Discussions on Aktiengesellschaft Bayer

No discussions yet.